跳至主要内容
临床试验/CTRI/2026/03/106616
CTRI/2026/03/106616尚未招募Unknown

A single blind clinical study to evaluate the activity of Honasa Skin Renew Peptide Under Eye Cream for dark circle and ageing.

Honasa Consumer Ltd.1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2026年3月23日

试验速览

阶段
Unknown
状态
尚未招募
发起方
入组人数
36
试验地点
1

研究概览

简要总结

A single blind one arm study. 

Each participant entering the trial will be assigned to a regimen of investigational product.

Day 0 (T0) - Baseline Measurements:

Skin Hydration (Corneometer): Day 0, Day 1(for 24 hour check), Day 14)

TEWL (Tewameter): (0 and 14 days)

Skin Melanin(Mexameter): (0 and 14 days)

Wrinkles (Visioface): ((0 and 14 days))

Skin Firmness/Elasticity(Cutometer Assessment): (0 and 14 days)

Dermatological Evaluations (5-Point Ordinal Scale,0-4): (0, 14days)

  1. Dark circle severity Score ( Day 0 and Day 14)- with image

  2. Eye puffiness Score ( Day 0 and Day 14)

  3. Crow feet grading with Photonumeric Scale ( Day 0 and Day 14)- with image

• HD Imaging with DSLR: (0, 14 days)

研究设计

研究类型
Observational

入排标准

年龄范围
25.00 Year(s) 至 45.00 Year(s)(—)

入选标准

  • Gender Male and Female aged between 25-
  • Non-pregnant, non-lactating female
  • Subject with crow feet and dark circle.
  • Subject willing to give written informed consent
  • Women of child bearing potential must have a negative urine pregnancy test.
  • Free of any systemic and dermatologic disorder, which in the opinion of the investigator, will interface with the study results or increase the risk of AE.
  • Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation, natural or artificial for the duration of the study.

排除标准

  • Subjects who are pregnant, breast feeding, or planning to become pregnant during the study
  • Volunteers with skin conditions such as eczema, psoriasis, etc
  • Have any evidence of systematic cancer, squamous cell carcinoma, basal cell carcinoma in the last 5 years, or any other confounding skin condition.
  • Have open sore or open lesions in the treatment area
  • Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product.
  • Have participated in any interventional clinical trial in the previous 30 days.
  • Have a known sensitivity to any of the constituents of the test product including sensitivities to any of the constituents.
  • Have used, are using, or are planning to use immunosuppressive or immunomodulatory medications (i.e., biologics), including corticosteroids.
  • Have a history of alcohol or illegal drug/ substance abuse or suspected alcohol or illegal drug/substance abuse in the past 2 years.

研究者

发起方
Honasa Consumer Ltd.
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Robin Chugh

CCFT Laboratories

研究点 (1)

Loading locations...

相似试验